Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Feasibility and acceptability of an animatronic duck intervention for promoting adaptation to the in-patient setting among pediatric patients receiving treatment for cancer.

Miller TP, Klosky JL, Zamora F, Swift M, Mertens AC.

Pediatr Blood Cancer. 2019 Sep 5:e27984. doi: 10.1002/pbc.27984. [Epub ahead of print]

PMID:
31486586
2.

Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, Bagatell R, Adamson PC, Aplenc R.

Pediatr Blood Cancer. 2019 Jul;66(7):e27747. doi: 10.1002/pbc.27747. Epub 2019 Apr 9.

PMID:
30968531
3.

Issues and Opportunities on Implementing an Online Faculty Review System.

Erstad BL, Oxnam MG, Miller TP, Draugalis JR.

Am J Pharm Educ. 2018 Apr;82(3):6911. doi: 10.5688/ajpe6911.

4.

Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia.

Fitzgerald JC, Li Y, Fisher BT, Huang YS, Miller TP, Bagatell R, Seif AE, Aplenc R, Thomas NJ.

Pediatr Crit Care Med. 2018 Jun;19(6):e312-e320. doi: 10.1097/PCC.0000000000001525.

5.

Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia.

Getz KD, Miller TP, Seif AE, Li Y, Huang YV, Fisher BT, Aplenc R.

PLoS One. 2018 Feb 8;13(2):e0192529. doi: 10.1371/journal.pone.0192529. eCollection 2018.

6.

Complications preceding early deaths in Black and White children with acute myeloid leukemia.

Winestone LE, Getz KD, Miller TP, Li Y, Huang YS, Seif AE, Fisher BT, Aplenc R.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26712. Epub 2017 Jul 20.

7.

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

Haematologica. 2017 Sep;102(9):e340-e343. doi: 10.3324/haematol.2017.168815. Epub 2017 Jun 22. No abstract available.

8.

Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia.

Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL.

Cancer. 2017 Oct 1;123(19):3781-3790. doi: 10.1002/cncr.30792. Epub 2017 May 23. Erratum in: Cancer. 2018 Apr 15;124(8):1841-1844.

9.

Reply to H.S.L. Jim et al.

Miller TP, Aplenc R.

J Clin Oncol. 2017 Apr 1;35(10):1135. doi: 10.1200/JCO.2016.70.9253. Epub 2017 Feb 6. No abstract available.

PMID:
28165896
10.

Using electronic medical record data to report laboratory adverse events.

Miller TP, Li Y, Getz KD, Dudley J, Burrows E, Pennington J, Ibrahimova A, Fisher BT, Bagatell R, Seif AE, Grundmeier R, Aplenc R.

Br J Haematol. 2017 Apr;177(2):283-286. doi: 10.1111/bjh.14538. Epub 2017 Feb 1.

11.

The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.

Winestone LE, Getz KD, Miller TP, Wilkes JJ, Sack L, Li Y, Huang YS, Seif AE, Bagatell R, Fisher BT, Epstein AJ, Aplenc R.

Am J Hematol. 2017 Feb;92(2):141-148. doi: 10.1002/ajh.24605. Epub 2016 Dec 7.

12.

Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.

Rao P, Li Y, Getz KD, Miller TP, Huang YS, Wilkes JJ, Seif AE, Bagatell R, Fisher BT, Gracia C, Aplenc R.

Cancer. 2016 Nov 15;122(21):3394-3400. doi: 10.1002/cncr.30225. Epub 2016 Sep 12.

13.

Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report.

Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Alonzo T, Gerbing R, Sung L, Hall M, Bagatell R, Gamis A, Fisher BT, Aplenc R.

Cancer Med. 2016 Sep;5(9):2412-6. doi: 10.1002/cam4.839. Epub 2016 Jul 29.

14.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ.

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5. No abstract available.

15.

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16.

16.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO.

Leuk Lymphoma. 2016 Oct;57(10):2359-69. doi: 10.3109/10428194.2015.1135431. Epub 2016 Jan 12.

17.

A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R.

Leuk Lymphoma. 2016 Jul;57(7):1567-74. doi: 10.3109/10428194.2015.1088652. Epub 2016 Jan 4.

18.

A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.

Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R.

Cancer Med. 2015 Sep;4(9):1356-64. doi: 10.1002/cam4.481. Epub 2015 Jun 24.

19.

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.

Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R.

Pediatr Blood Cancer. 2015 Oct;62(10):1775-81. doi: 10.1002/pbc.25569. Epub 2015 May 6.

20.

Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.

Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R.

Pediatr Blood Cancer. 2015 Jul;62(7):1184-9. doi: 10.1002/pbc.25475. Epub 2015 Mar 11.

21.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI.

Blood. 2015 Jan 8;125(2):236-41. doi: 10.1182/blood-2014-06-584623. Epub 2014 Nov 13.

22.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM.

Blood. 2014 Aug 21;124(8):1259-65. doi: 10.1182/blood-2014-04-570044. Epub 2014 Jul 11.

23.

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.

Mahadevan D, Morales C, Cooke LS, Manziello A, Mount DW, Persky DO, Fisher RI, Miller TP, Qi W.

PLoS One. 2014 Jun 3;9(6):e95184. doi: 10.1371/journal.pone.0095184. eCollection 2014.

24.

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI.

Br J Haematol. 2014 Aug;166(3):382-9. doi: 10.1111/bjh.12906. Epub 2014 Apr 18.

25.

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.

Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM.

Am J Hematol. 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12.

26.

Heart of lymphoma: primary mediastinal large B-cell lymphoma with endomyocardial involvement.

Rogowitz E, Babiker HM, Krishnadasan R, Jokerst C, Miller TP, Bookman M.

Case Rep Oncol Med. 2013;2013:814291. doi: 10.1155/2013/814291. Epub 2013 Oct 1.

27.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI.

N Engl J Med. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077.

28.

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15.

29.

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI.

Ann Oncol. 2013 Jun;24(6):1587-93. doi: 10.1093/annonc/mdt070. Epub 2013 Mar 15.

30.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF.

Blood. 2013 May 2;121(18):3547-53. doi: 10.1182/blood-2012-09-454694. Epub 2013 Feb 5.

31.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ.

Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29.

32.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.

33.

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D.

Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12.

34.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR.

Ann Oncol. 2013 Feb;24(2):441-8. doi: 10.1093/annonc/mds429. Epub 2012 Oct 5.

PMID:
23041589
35.

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP.

J Clin Oncol. 2012 Sep 20;30(27):3368-75. doi: 10.1200/JCO.2011.40.6546. Epub 2012 Aug 20.

36.

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP.

Cancer. 2013 Jan 15;119(2):371-9. doi: 10.1002/cncr.27733. Epub 2012 Jul 25.

37.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.

Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25.

38.

Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.

Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR.

Cancer. 2012 Oct 1;118(19):4842-50. doi: 10.1002/cncr.27513. Epub 2012 Mar 20.

39.

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W.

Clin Cancer Res. 2012 Apr 15;18(8):2210-9. doi: 10.1158/1078-0432.CCR-11-2413. Epub 2012 Feb 28. Erratum in: Clin Cancer Res. 2015 Nov 15;21(22):5181.

40.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM.

Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22.

41.

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D.

Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19.

42.

Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP.

Pediatr Blood Cancer. 2011 Sep;57(3):492-8. doi: 10.1002/pbc.23060. Epub 2011 May 10.

43.

Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.

Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, Tubbs RR, Braziel RM, Delabie J, Miller TP, Staudt LM.

Clin Cancer Res. 2011 Jun 1;17(11):3727-32. doi: 10.1158/1078-0432.CCR-10-2573. Epub 2011 Mar 1.

44.

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D.

Biochem Pharmacol. 2011 Apr 1;81(7):881-90. doi: 10.1016/j.bcp.2011.01.017. Epub 2011 Feb 1.

45.

Sec5, a member of the exocyst complex, mediates Drosophila embryo cellularization.

Murthy M, Teodoro RO, Miller TP, Schwarz TL.

Development. 2010 Aug;137(16):2773-83. doi: 10.1242/dev.048330. Epub 2010 Jul 14.

46.

Analysis & commentary. Health reform: only a cease-fire in a political hundred years' war.

Miller TP.

Health Aff (Millwood). 2010 Jun;29(6):1101-5. doi: 10.1377/hlthaff.2010.0439.

PMID:
20530337
47.

How can we make more progress in measuring physicians' performance to improve the value of care?

Miller TP, Brennan TA, Milstein A.

Health Aff (Millwood). 2009 Sep-Oct;28(5):1429-37. doi: 10.1377/hlthaff.28.5.1429.

PMID:
19738260
48.

Localized large cell lymphoma: is there any need for radiation therapy?

Persky DO, Miller TP.

Curr Opin Oncol. 2009 Sep;21(5):401-6. doi: 10.1097/CCO.0b013e32832f3c8b. Review.

PMID:
19593138
49.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP.

Leuk Lymphoma. 2009 May;50(5):728-35. doi: 10.1080/10428190902856808.

50.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI.

J Clin Oncol. 2009 Jan 1;27(1):114-9. doi: 10.1200/JCO.2008.16.8021. Epub 2008 Dec 1.

Supplemental Content

Loading ...
Support Center